The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Open accessAbstract
Poly-(ADP)-ribose polymerase (PARP) inhibition is synthetic lethal with deficiency for homologous recombination (HR), a pathway essential for DNA double-strand break repair. PARP inhibitors (PARPi) therefore hold great promise for the treatment of tumors with disruptive mutations in BRCA1/2 or other HR factors. Unfortunately, PARPi resistance has proved to be a major problem in the clinic. Knowledge about PARPi resistance is expanding quickly, revealing four main mechanisms that alter drug availability, affect (de)PARylation enzymes, restore HR, or restore replication fork stability. We discuss how studies on resistance mechanisms have yielded important insights into the regulation of DNA double-strand break (DSB) repair and replication fork protection, and how these studies could pave the way for novel treatment options to target resistance mechanisms or acquired vulnerabilities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A mechanism for the suppression of homologous recombination in G1 cells
Orthwein, A., Noordermeer, S. M., Wilson, M. D., Landry, S., Enchev, R. I., Sherker, A., Munro, M., Pinder, J., Salsman, J., Dellaire, G., et al. (2015) · Nature · doi:10.1038/nature16142 · Cited by 471
Self-citationRetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Huey, B., & King, M.-C. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,550
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671
Somatic mutation in cancer and normal cells
Martincorena, I., & Campbell, P. J. (2015) · Science · doi:10.1126/science.aab4082 · Cited by 1,396
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Schlacher, K., Christ, N., Siaud, N., Egashira, A., Wu, H., & Jasin, M. (2011) · Cell · doi:10.1016/j.cell.2011.03.041 · Cited by 1,255
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Schlacher, K., Wu, H., & Jasin, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.015 · Cited by 936
Replication fork stability confers chemoresistance in BRCA-deficient cells
Ray Chaudhuri, A., Callen, E., Ding, X., Gogola, E., Duarte, A. A., Lee, J.-E., Wong, N., Lafarga, V., Calvo, J. A., Panzarino, N. J., et al. (2016) · Nature · doi:10.1038/nature18325 · Cited by 930
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Ceccaldi, R., Liu, J. C., Amunugama, R., Hajdu, I., Primack, B., Petalcorin, M. I. R., O’Connor, K. W., Konstantinopoulos, P. A., Elledge, S. J., Boulton, S. J., et al. (2015) · Nature · doi:10.1038/nature14184 · Cited by 903
Escribano-Díaz, C., Orthwein, A., Fradet-Turcotte, A., Xing, M., Young, J. T. F., Tkáč, J., Cook, M. A., Rosebrock, A. P., Munro, M., Canny, M. D., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.001 · Cited by 900
Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination
Mateos-Gomez, P. A., Gong, F., Nair, N., Miller, K. M., Lazzerini-Denchi, E., & Sfeir, A. (2015) · Nature · doi:10.1038/nature14157 · Cited by 765
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J., Takeda, S., Morris, J., Teicher, B., Doroshow, J. H., & Pommier, Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 756
PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) Polymerase
Amé, J.-C., Rolli, V., Schreiber, V., Niedergang, C., Apiou, F., Decker, P., Muller, S., Höger, T., Murcia, J. M.-D., & de Murcia, G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.17860 · Cited by 745
The shieldin complex mediates 53BP1-dependent DNA repair
Noordermeer, S. M., Adam, S., Setiaputra, D., Barazas, M., Pettitt, S. J., Ling, A. K., Olivieri, M., Álvarez-Quilón, A., Moatti, N., Zimmermann, M., et al. (2018) · Nature · doi:10.1038/s41586-018-0340-7 · Cited by 645
Self-citationChapman, J. R., Barral, P., Vannier, J.-B., Borel, V., Steger, M., Tomas-Loba, A., Sartori, A. A., Adams, I. R., Batista, F. D., & Boulton, S. J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.002 · Cited by 606
53BP1 Regulates DSB Repair Using Rif1 to Control 5′ End Resection
Zimmermann, M., Lottersberger, F., Buonomo, S. B., Sfeir, A., & de Lange, T. (2013) · Science · doi:10.1126/science.1231573 · Cited by 603
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
Xu, G., Chapman, J. R., Brandsma, I., Yuan, J., Mistrik, M., Bouwman, P., Bartkova, J., Gogola, E., Warmerdam, D., Barazas, M., et al. (2015) · Nature · doi:10.1038/nature14328 · Cited by 593
ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2
Beucher, A., Birraux, J., Tchouandong, L., Barton, O., Shibata, A., Conrad, S., Goodarzi, A. A., Krempler, A., Jeggo, P. A., & Löbrich, M. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.276 · Cited by 553
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 541
High speed of fork progression induces DNA replication stress and genomic instability
Maya-Mendoza, A., Moudry, P., Merchut-Maya, J. M., Lee, M., Strauss, R., & Bartek, J. (2018) · Nature · doi:10.1038/s41586-018-0261-5 · Cited by 514
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A., Boon, U., Sol, W., van Deemter, L., Zander, S. A., Drost, R., Wientjens, E., Ji, J., Aly, A., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 514
Human CtIP Mediates Cell Cycle Control of DNA End Resection and Double Strand Break Repair
Huertas, P., & Jackson, S. P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808906200 · Cited by 511
Topoisomerase I poisoning results in PARP-mediated replication fork reversal
Ray Chaudhuri, A., Hashimoto, Y., Herrador, R., Neelsen, K. J., Fachinetti, D., Bermejo, R., Cocito, A., Costanzo, V., & Lopes, M. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2258 · Cited by 499
Factors determining DNA double‐strand break repair pathway choice in G2 phase
Shibata, A., Conrad, S., Birraux, J., Geuting, V., Barton, O., Ismail, A., Kakarougkas, A., Meek, K., Taucher‐Scholz, G., Löbrich, M., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.27 · Cited by 479
Regulation of Single-Strand Annealing and its Role in Genome Maintenance
Bhargava, R., Onyango, D. O., & Stark, J. M. (2016) · Trends in Genetics · doi:10.1016/j.tig.2016.06.007 · Cited by 473
Gupta, R., Somyajit, K., Narita, T., Maskey, E., Stanlie, A., Kremer, M., Typas, D., Lammers, M., Mailand, N., Nussenzweig, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.050 · Cited by 469
Pettitt, S. J., Krastev, D. B., Brandsma, I., Dréan, A., Song, F., Aleksandrov, R., Harrell, M. I., Menon, M., Brough, R., Campbell, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03917-2 · Cited by 449
Bruna, A., Rueda, O. M., Greenwood, W., Batra, A. S., Callari, M., Batra, R. N., Pogrebniak, K., Sandoval, J., Cassidy, J. W., Tufegdzic-Vidakovic, A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.041 · Cited by 448
Cruz, C., Castroviejo-Bermejo, M., Gutiérrez-Enríquez, S., Llop-Guevara, A., Ibrahim, Y. H., Gris-Oliver, A., Bonache, S., Morancho, B., Bruna, A., Rueda, O. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy099 · Cited by 433
Lin, K. K., Harrell, M. I., Oza, A. M., Oaknin, A., Ray-Coquard, I., Tinker, A. V., Helman, E., Radke, M. R., Say, C., Vo, L.-T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0715 · Cited by 432
53BP1–RIF1–shieldin counteracts DSB resection through CST- and Polα-dependent fill-in
Mirman, Z., Lottersberger, F., Takai, H., Kibe, T., Gong, Y., Takai, K., Bianchi, A., Zimmermann, M., Durocher, D., & de Lange, T. (2018) · Nature · doi:10.1038/s41586-018-0324-7 · Cited by 427
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Goodall, J., Mateo, J., Yuan, W., Mossop, H., Porta, N., Miranda, S., Perez-Lopez, R., Dolling, D., Robinson, D. R., Sandhu, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0261 · Cited by 421
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
Dev, H., Chiang, T.-W. W., Lescale, C., de Krijger, I., Martin, A. G., Pilger, D., Coates, J., Sczaniecka-Clift, M., Wei, W., Ostermaier, M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0140-1 · Cited by 417
Lemaçon, D., Jackson, J., Quinet, A., Brickner, J. R., Li, S., Yazinski, S., You, Z., Ira, G., Zou, L., Mosammaparast, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01180-5 · Cited by 416
Kondrashova, O., Nguyen, M., Shield-Artin, K., Tinker, A. V., Teng, N. N. H., Harrell, M. I., Kuiper, M. J., Ho, G.-Y., Barker, H., Jasin, M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0419 · Cited by 407
BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.
Yuan, S. F., Lee, S. Y., Chen, G., Song, M., Tomlinson, G. E., & Lee, E. Y.-H. P. (1999) · PubMed · Cited by 404
Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching
Di Virgilio, M., Callen, E., Yamane, A., Zhang, W., Jankovic, M., Gitlin, A. D., Feldhahn, N., Resch, W., Oliveira, T. Y., Chait, B. T., et al. (2013) · Science · doi:10.1126/science.1230624 · Cited by 401
CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions
Zimmermann, M., Murina, O., Reijns, M. A. M., Agathanggelou, A., Challis, R., Tarnauskaitė, Ž., Muir, M., Fluteau, A., Aregger, M., McEwan, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0291-z · Cited by 401
Yazinski, S. A., Comaills, V., Buisson, R., Genois, M.-M., Nguyen, H. D., Ho, C. K., Todorova Kwan, T., Morris, R., Lauffer, S., Nussenzweig, A., et al. (2017) · Genes & Development · doi:10.1101/gad.290957.116 · Cited by 395
Taglialatela, A., Alvarez, S., Leuzzi, G., Sannino, V., Ranjha, L., Huang, J.-W., Madubata, C., Anand, R., Levy, B., Rabadan, R., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.036 · Cited by 394
BRCA1–BARD1 promotes RAD51-mediated homologous DNA pairing
Zhao, W., Steinfeld, J. B., Liang, F., Chen, X., Maranon, D. G., Jian Ma, C., Kwon, Y., Rao, T., Wang, W., Sheng, C., et al. (2017) · Nature · doi:10.1038/nature24060 · Cited by 393
Hanzlikova, H., Kalasova, I., Demin, A. A., Pennicott, L. E., Cihlarova, Z., & Caldecott, K. W. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.004 · Cited by 393
Mladenov, E., & Iliakis, G. (2011) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2011.02.005 · Cited by 381
Gogola, E., Duarte, A. A., de Ruiter, J. R., Wiegant, W. W., Schmid, J. A., de Bruijn, R., James, D. I., Guerrero Llobet, S., Vis, D. J., Annunziato, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.008 · Cited by 374
Self-citationBajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2541 · Cited by 373
Vaidyanathan, A., Sawers, L., Gannon, A.-L., Chakravarty, P., Scott, A. L., Bray, S. E., Ferguson, M. J., & Smith, G. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.203 · Cited by 364
Miyake, Y., Nakamura, M., Nabetani, A., Shimamura, S., Tamura, M., Yonehara, S., Saito, M., & Ishikawa, F. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.08.009 · Cited by 350
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Barber, L. J., Sandhu, S., Chen, L., Campbell, J., Kozarewa, I., Fenwick, K., Assiotis, I., Rodrigues, D. N., Reis-Filho, J. S., Moreno, V., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4140 · Cited by 336
Rondinelli, B., Gogola, E., Yücel, H., Duarte, A. A., van de Ven, M., van der Sluijs, R., Konstantinopoulos, P. A., Jonkers, J., Ceccaldi, R., Rottenberg, S., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3626 · Cited by 332
BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair
Chapman, J. R., Sossick, A. J., Boulton, S. J., & Jackson, S. P. (2012) · Journal of Cell Science · doi:10.1242/jcs.105353 · Cited by 327
Telomeric 3′ Overhangs Derive from Resection by Exo1 and Apollo and Fill-In by POT1b-Associated CST
Wu, P., Takai, H., & de Lange, T. (2012) · Cell · doi:10.1016/j.cell.2012.05.026 · Cited by 321
53BP1 cooperation with the REV7–shieldin complex underpins DNA structure-specific NHEJ
Ghezraoui, H., Oliveira, C., Becker, J. R., Bilham, K., Moralli, D., Anzilotti, C., Fischer, R., Deobagkar-Lele, M., Sanchiz-Calvo, M., Fueyo-Marcos, E., et al. (2018) · Nature · doi:10.1038/s41586-018-0362-1 · Cited by 320
Fisher, A. E. O., Hochegger, H., Takeda, S., & Caldecott, K. W. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02248-06 · Cited by 314
Cao, L., Xu, X., Bunting, S. F., Liu, J., Wang, R.-H., Cao, L. L., Wu, J. J., Peng, T.-N., Chen, J., Nussenzweig, A., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.037 · Cited by 309
Rottenberg, S., Nygren, A. O. H., Pajic, M., van Leeuwen, F. W. B., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G., van Tellingen, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702955104 · Cited by 304
MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5′ end resection
Boersma, V., Moatti, N., Segura-Bayona, S., Peuscher, M. H., van der Torre, J., Wevers, B. A., Orthwein, A., Durocher, D., & Jacobs, J. J. L. (2015) · Nature · doi:10.1038/nature14216 · Cited by 304
Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN
Arnoult, N., Correia, A., Ma, J., Merlo, A., Garcia-Gomez, S., Maric, M., Tognetti, M., Benner, C. W., Boulton, S. J., Saghatelian, A., et al. (2017) · Nature · doi:10.1038/nature24023 · Cited by 299
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Murai, J., Feng, Y., Yu, G. K., Ru, Y., Tang, S.-W., Shen, Y., & Pommier, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12266 · Cited by 297
Johnson, S. F., Cruz, C., Greifenberg, A. K., Dust, S., Stover, D. G., Chi, D., Primack, B., Cao, S., Bernhardy, A. J., Coulson, R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.077 · Cited by 291
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Johnson, N., Li, Y.-C., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., Moreau, L. A., Unitt, C., Bronson, R. T., Thomas, H. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2377 · Cited by 290
Human BRCA1–BARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection
Densham, R. M., Garvin, A. J., Stone, H. R., Strachan, J., Baldock, R. A., Daza-Martin, M., Fletcher, A., Blair-Reid, S., Beesley, J., Johal, B., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3236 · Cited by 290
SLFN11 Blocks Stressed Replication Forks Independently of ATR
Murai, J., Tang, S.-W., Leo, E., Baechler, S. A., Redon, C. E., Zhang, H., Al Abo, M., Rajapakse, V. N., Nakamura, E., Jenkins, L. M. M., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.01.012 · Cited by 275
Quigley, D., Alumkal, J. J., Wyatt, A. W., Kothari, V., Foye, A., Lloyd, P., Aggarwal, R., Kim, W., Lu, E., Schwartzman, J., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0146 · Cited by 273
RIF1 Counteracts BRCA1-mediated End Resection during DNA Repair
Feng, L., Fong, K.-W., Wang, J., Wang, W., & Chen, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.457440 · Cited by 272
Konstantinopoulos, P. A., Barry, W. T., Birrer, M., Westin, S. N., Cadoo, K. A., Shapiro, G. I., Mayer, E. L., O'Cearbhaill, R. E., Coleman, R. L., Kochupurakkal, B., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30905-7 · Cited by 263
Weigelt, B., Comino-Méndez, I., de Bruijn, I., Tian, L., Meisel, J. L., García-Murillas, I., Fribbens, C., Cutts, R., Martelotto, L. G., Ng, C. K. Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0544 · Cited by 263
Partial rescue of Brca15–6 early embryonic lethality by p53 or p21 null mutation
Hakem, R., de la Pompa, J. L., Elia, A., Potter, J., & Mak, T. W. (1997) · Nature Genetics · doi:10.1038/ng0797-298 · Cited by 252
BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair
Bunting, S. F., Callén, E., Kozak, M. L., Kim, J. M., Wong, N., López-Contreras, A. J., Ludwig, T., Baer, R., Faryabi, R. B., Malhowski, A., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.02.015 · Cited by 252
Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects
Evers, B., & Jonkers, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209871 · Cited by 251
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells
He, Y. J., Meghani, K., Caron, M.-C., Yang, C., Ronato, D. A., Bian, J., Sharma, A., Moore, J., Niraj, J., Detappe, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0670-5 · Cited by 219
ter Brugge, P., Kristel, P., van der Burg, E., Boon, U., de Maaker, M., Lips, E., Mulder, L., de Ruiter, J., Moutinho, C., Gevensleben, H., et al. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw148 · Cited by 211
Dungrawala, H., Bhat, K. P., Le Meur, R., Chazin, W. J., Ding, X., Sharan, S. K., Wessel, S. R., Sathe, A. A., Zhao, R., & Cortez, D. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.023 · Cited by 200
Joshi, P. M., Sutor, S. L., Huntoon, C. J., & Karnitz, L. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551143 · Cited by 199
H4K20me0 recognition by BRCA1–BARD1 directs homologous recombination to sister chromatids
Nakamura, K., Saredi, G., Becker, J. R., Foster, B. M., Nguyen, N. V., Beyer, T. E., Cesa, L. C., Faull, P. A., Lukauskas, S., Frimurer, T., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0282-9 · Cited by 199
Christie, E. L., Fereday, S., Doig, K., Pattnaik, S., Dawson, S.-J., & Bowtell, D. D. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4627 · Cited by 196
Gourley, C., Balmaña, J., Ledermann, J. A., Serra, V., Dent, R., Loibl, S., Pujade-Lauraine, E., & Boulton, S. J. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02050 · Cited by 194
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer
Christie, E. L., Pattnaik, S., Beach, J., Copeland, A., Rashoo, N., Fereday, S., Hendley, J., Alsop, K., Brady, S. L., Lamb, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09312-9 · Cited by 193
Hanzlikova, H., Gittens, W., Krejcikova, K., Zeng, Z., & Caldecott, K. W. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1246 · Cited by 192
Min, A., Im, S.-A., Kim, D. K., Song, S.-H., Kim, H.-J., Lee, K.-H., Kim, T.-Y., Han, S.-W., Oh, D.-Y., Kim, T.-Y., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0534-y · Cited by 177
Preserving replication fork integrity and competence via the homologous recombination pathway
Ait Saada, A., Lambert, S. A. E., & Carr, A. M. (2018) · DNA Repair · doi:10.1016/j.dnarep.2018.08.017 · Cited by 173
Pettitt, S. J., Rehman, F. L., Bajrami, I., Brough, R., Wallberg, F., Kozarewa, I., Fenwick, K., Assiotis, I., Chen, L., Campbell, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061520 · Cited by 172
HELB Is a Feedback Inhibitor of DNA End Resection
Tkáč, J., Xu, G., Adhikary, H., Young, J. T. F., Gallo, D., Escribano‐Diaz, C., Krietsch, J., Orthwein, A., Munro, M., Sol, W., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2015.12.013 · Cited by 168
Barazas, M., Annunziato, S., Pettitt, S. J., de Krijger, I., Ghezraoui, H., Roobol, S. J., Lutz, C., Frankum, J. R., Song, F., Brough, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.046 · Cited by 165
Polymerase theta-mediated end joining of replication-associated DNA breaks in C. elegans
Roerink, S. F., van Schendel, R., & Tijsterman, M. (2014) · Genome Research · doi:10.1101/gr.170431.113 · Cited by 160
BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance
Duarte, A. A., Gogola, E., Sachs, N., Barazas, M., Annunziato, S., de Ruiter, J. R., Velds, A., Blatter, S., Houthuijzen, J. M., van de Ven, M., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4535 · Cited by 152
Choi, Y. E., Meghani, K. A., Brault, M. E., Leclerc, L., He, Y. J., Day, T. A., Elias, K. M., Drapkin, R., Weinstock, D. M., Dao, F., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.046 · Cited by 149
SHLD2/FAM35A co‐operates with REV7 to coordinate DNA double‐strand break repair pathway choice
Findlay, S., Heath, J., Luo, V. M., Malina, A., Morin, T., Coulombe, Y., Djerir, B., Li, Z., Samiei, A., Simo‐Cheyou, E. R., et al. (2018) · The EMBO Journal · doi:10.15252/embj.2018100158 · Cited by 148
Latest clinical evidence and further development of PARP inhibitors in ovarian cancer
Mirza, M. R., Pignata, S., & Ledermann, J. A. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy174 · Cited by 134
Konstantinopoulos, P. A., Wilson, A. J., Saskowski, J. L., Wass, E., & Khabele, D. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.03.007 · Cited by 116
BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation
Zong, D., Adam, S., Wang, Y., Sasanuma, H., Callén, E., Murga, M., Day, A., Kruhlak, M. J., Wong, N., Munro, M., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.12.010 · Cited by 116
Lo, K. W. ‐., Kan, H.-M., Chan, L.-N., Xu, W., Wang, K., Wu, Z., Sheng, M., & Zhang, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411408200 · Cited by 114
FAM35A associates with REV7 and modulates DNA damage responses of normal and BRCA1‐defective cells
Tomida, J., Takata, K., Bhetawal, S., Person, M. D., Chao, H., Tang, D. G., & Wood, R. D. (2018) · The EMBO Journal · doi:10.15252/embj.201899543 · Cited by 108
Lai, X., Broderick, R., Bergoglio, V., Zimmer, J., Badie, S., Niedźwiedź, W., Hoffmann, J., & Tarsounas, M. (2017) · Nature Communications · doi:10.1038/ncomms15983 · Cited by 107
Becker, J. R., Cuella-Martin, R., Barazas, M., Liu, R., Oliveira, C., Oliver, A. W., Bilham, K., Holt, A. B., Blackford, A. N., Heierhorst, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07855-x · Cited by 107
O’Connor, L. O., Rulten, S. L., Cranston, A. N., Odedra, R., Brown, H., Jaspers, J. E., Jones, L., Knights, C., Evers, B., Ting, A. K. T., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3240 · Cited by 104
Nacson, J., Krais, J. J., Bernhardy, A. J., Clausen, E., Feng, W., Wang, Y., Nicolas, É., Cai, K. Q., Tricarico, R., Hua, X., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.086 · Cited by 104
Poly(ADP-ribose) glycohydrolase silencing protects against H2O2-induced cell death
Blenn, C., Althaus, F. R., & Malanga, M. (2006) · Biochemical Journal · doi:10.1042/bj20051696 · Cited by 103
Gravells, P., Grant, E. K., Smith, K. M., James, D. I., & Bryant, H. E. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.02.010 · Cited by 97
BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer
Shimelis, H., Mesman, R. L. S., Nicolai, C. V., Ehlén, Å., Guidugli, L., Martin, C. A., Calléja, F. M. G. R., Meeks, H., Hallberg, E., Hinton, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2568 · Cited by 97
Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells
Fathers, C., Drayton, R. M., Solovieva, S. E., & Bryant, H. E. (2012) · Cell Cycle · doi:10.4161/cc.11.5.19482 · Cited by 94
Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP
Chao, O. S., & Goodman, O. B. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0173 · Cited by 94
Luijsterburg, M. S., Typas, D., Caron, M., Wiegant, W. W., van den Heuvel, D., Boonen, R. A. C. M., Couturier, A. M., Mullenders, L. H. F., Masson, J., & van Attikum, H. (2017) · eLife · doi:10.7554/elife.20922 · Cited by 94
CTC1-mediated C-strand fill-in is an essential step in telomere length maintenance
Feng, X., Hsu, S.-J., Kasbek, C., Fedor‐Chaiken, M., & Price, C. M. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx125 · Cited by 93
An OB-fold complex controls the repair pathways for DNA double-strand breaks
Gao, S., Feng, S., Ning, S., Liu, J., Zhao, H., Xu, Y., Shang, J., Li, K., Li, Q., Guo, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06407-7 · Cited by 93
Lheureux, S., Bruce, J. P., Burnier, J. V., Karakasis, K., Shaw, P. A., Clarke, B. A., Yang, S. Y. C., Quevedo, R., Li, T., Dowar, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3677 · Cited by 92
PARP Inhibitors as P-glyoprotein Substrates
Lawlor, D., Martin, P., Busschots, S., Thery, J., O’Leary, J. J., Hennessy, B. T., & Stordal, B. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23952 · Cited by 88
Role of 53BP1 oligomerization in regulating double-strand break repair
Lottersberger, F., Bothmer, A., Robbiani, D. F., Nussenzweig, M. C., & de Lange, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222617110 · Cited by 85
Pishvaian, M. J., Biankin, A. V., Bailey, P. J., Chang, D. K.-F., Laheru, D. A., Wolfgang, C. L., & Brody, J. R. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.40 · Cited by 80
BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance
Jaspers, J. E., Sol, W., Kersbergen, A. J., Schlicker, A., Guyader, C., Xu, G., Wessels, L. F. A., Borst, P., Jonkers, J., & Rottenberg, S. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0839 · Cited by 77
Gao, H., Coyle, D. L., Meyer‐Ficca, M. L., Meyer, R. G., Jacobson, E. L., Wang, Z., & Jacobson, M. K. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.12.025 · Cited by 63
RNF8 Regulates Assembly of RAD51 at DNA Double-Strand Breaks in the Absence of BRCA1 and 53BP1
Nakada, S., Yonamine, R. M., & Matsuo, K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1057 · Cited by 62
Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors
Barazas, M., Gasparini, A., Huang, Y., Küçükosmanoğlu, A., Annunziato, S., Bouwman, P., Sol, W., Kersbergen, A. J., Proost, N., de Korte‐Grimmerink, R., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2077 · Cited by 58
Gornstein, E. L., Sandefur, S., Chung, J., Gay, L. M., Holmes, O., Erlich, R., Soman, S., Martin, L.-A., Rose, A. V., Stephens, P. J., et al. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.12.010 · Cited by 49
BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
Vos, S., Moelans, C. B., & van Diest, P. J. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0856-z · Cited by 48
PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency
Noll, A., Illuzzi, G., Amé, J., Dantzer, F., & Schreiber, V. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0333-2 · Cited by 31
BRCA1 reversion mutation acquired after treatment identified by liquid biopsy
Mayor, P. C., Gay, L. M., Lele, S., & Elvin, J. A. (2017) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2017.06.010 · Cited by 30
Signatures of DNA-Repair Deficiencies in Breast Cancer
Turner, N. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmcibr1710161 · Cited by 26
Nacson, J., Krais, J. J., Bernhardy, A. J., Clausen, E., Feng, W., Wang, Y., Nicolas, É., Cai, K. Q., Tricarico, R., Hua, X., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.009 · Cited by 26
Kringen, P., Wang, Y., Dumeaux, V., Nesland, J., Kristensen, G., Børresen-Dale, A., & Dørum, A. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-134 · Cited by 17
Cited by
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 719
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
Molecular mechanisms of tumor resistance to radiotherapy
Wu, Y., Song, Y., Wang, R., & Wang, T. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01801-2 · Cited by 527
The forefront of ovarian cancer therapy: update on PARP inhibitors
Mirza, M. R., Coleman, R. L., González-Martín, A., Moore, K. N., Colombo, N., Ray-Coquard, I., & Pignata, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.004 · Cited by 365
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Metadata
- Authors
- Noordermeer, S. M., & van Attikum, H.
- Venue
- Trends in Cell Biology
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 29
- Issue
- 10
- Pages
- 820-834
- ISSN
- 0962-8924 (ISSN-L)
- OpenAlex
- W2968820602
- Cited by
- 456
- References
- 130
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.